Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois; Interdisciplinary Scientist Training Program, University of Chicago, Chicago, Illinois.
Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois.
Biol Psychiatry. 2019 Nov 15;86(10):792-800. doi: 10.1016/j.biopsych.2019.05.019. Epub 2019 Jun 3.
Numerous anecdotal reports suggest that repeated use of very low doses of lysergic acid diethylamide (LSD), known as microdosing, improves mood and cognitive function. These effects are consistent both with the known actions of LSD on serotonin receptors and with limited evidence that higher doses of LSD (100-200 μg) positively bias emotion processing. Yet, the effects of such subthreshold doses of LSD have not been tested in a controlled laboratory setting. As a first step, we examined the effects of single very low doses of LSD (0-26 μg) on mood and behavior in healthy volunteers under double-blind conditions.
Healthy young adults (N = 20) attended 4 laboratory sessions during which they received 0 (placebo), 6.5, 13, or 26 μg of LSD in randomized order at 1-week intervals. During expected peak drug effect, they completed mood questionnaires and behavioral tasks assessing emotion processing and cognition. Cardiovascular measures and body temperature were also assessed.
LSD produced dose-related subjective effects across the 3 doses (6.5, 13, and 26 μg). At the highest dose, the drug also increased ratings of vigor and slightly decreased positivity ratings of images with positive emotional content. Other mood measures, cognition, and physiological measures were unaffected.
Single microdoses of LSD produced orderly dose-related subjective effects in healthy volunteers. These findings indicate that a threshold dose of 13 μg of LSD might be used safely in an investigation of repeated administrations. It remains to be determined whether the drug improves mood or cognition in individuals with symptoms of depression.
大量传闻报告表明,反复使用极低剂量的麦角酸二乙酰胺(LSD),即所谓的微量用药,可以改善情绪和认知功能。这些效果既与 LSD 对血清素受体的已知作用一致,也与有限的证据一致,即更高剂量的 LSD(100-200μg)可以积极地影响情绪处理。然而,这种阈下剂量的 LSD 的效果尚未在受控的实验室环境中进行测试。作为第一步,我们在双盲条件下,检查了单次极低剂量 LSD(0-26μg)对健康志愿者的情绪和行为的影响。
健康的年轻成年人(N=20)参加了 4 次实验室会议,在 1 周的间隔内以随机顺序接受 0(安慰剂)、6.5、13 或 26μg 的 LSD。在预期的药物高峰作用期间,他们完成了情绪问卷和行为任务,评估情绪处理和认知。心血管测量和体温也进行了评估。
LSD 在 3 个剂量(6.5、13 和 26μg)下产生了剂量相关的主观效果。在最高剂量下,该药物还增加了活力评分,并略微降低了积极情绪内容图像的积极性评分。其他情绪测量、认知和生理测量不受影响。
单次微量 LSD 在健康志愿者中产生了有序的剂量相关主观效果。这些发现表明,13μg 的 LSD 阈值剂量可能安全地用于重复给药的研究。仍有待确定该药物是否能改善有抑郁症状的个体的情绪或认知。